Ordering patient medications is easy. With an online account, access our extensive formulary or over 20,000 unique items - 24 hours a day, 7 days a week.
Ordering your pet's prescription drugs from Wedgewood Pharmacy is safe, and convenient. With a prescription number, easily refill prescriptions and enroll in the AutoRefill Program.
Dogs and horses
May Be Prescribed by Vets for:
keratoconjunctivitis sicca (KCS),
Pannus (chronic superficial keratitis),
Search for Available Dosage Forms
Cyclosporine is non-cytotoxic. It inhibits T-helper cell activity and shifts the regulation of the immune response towards immune tolerance. Since T-cells orchestrate most chronic immune responses, cyclosporine has broad anti-inflammatory effects. Its original indication was to prevent rejection in organ transplantation patients; its systemic indications currently include many autoimmune disorders.
The first commercial ophthalmic cyclosporine was Optimmune®, a 0.2% cyclosporine ointment made by Schering Plough Animal Health. Optimmune® was approved in 1995 in the Unites States to treat canine KCS and approved in Europe for KCS and pannus. Compounded ophthalmic cyclosporine drops have been used commonly in 1.0-2.0% concentrations in corn oil when Optimmune® was either commercially unavailable or owners were physically unable to apply an ointment. An aqueous suspension of 0.05% cyclosporine (Restasis®) was developed by Allergan Pharmaceuticals for treatment of KCS in human patients.
Topical cyclosporine has several beneficial effects in dry-eye patients. One of these effects is to directly increase secretion of physiologic tears. Physiologic tears (as opposed to artificial tears) contain growth factors to regulate corneal cell turnover and healing, lysozyme and antibodies for infection control and numerous nutritional elements required for the health of the avascular cornea. Topical CsA appears to facilitate lymphocytic apoptosis and suppress epithelial cell apoptosis, allowing regeneration of lacrimal-gland tissue in dogs with KCS. Cyclosporine also restores conjunctival goblet-cell mucin production. Topical CsA is an effective therapy for aqueous deficiency and for mucin deficiency dry-eye disorders in dogs.
Approximately 80% of dogs with KCS will increase tearing when treated with topical CsA. A major determinant in the success or failure of the individual KCS patient appears to be the stage of KCS at which CsA treatment is initiated. The lacrimal glands in KCS become progressively atrophied over the course of the disease. Dogs with a Schirmer Tear Test (STT) of 0 mm/min often have complete atrophy of the lacrimal glands and cannot respond to CsA; early treatment of KCS is therefore advocated. Dogs with congenital aplasia of the lacrimal glands and dogs with neurologic etiologies of KCS also are unlikely to increase tearing with CsA. However, even in dogs where lacrimation cannot be restored with CsA, the anti-inflammatory effects on the cornea and conjunctiva and regulating mucus production can be beneficial. The majority of KCS dogs require lifelong CsA-treatment. Interruptions in therapy lead to relapse of KCS.
Topical CsA represents an important therapeutic addition for several autoimmune- and immune-mediated disorders of the ocular surface that previously were responsive only to corticosteroids. Dogs that receive chronic topical corticosteroids are in jeopardy of incurring a minor corneal abrasion, which, under the influence of corticosteroids and collagenase activation, may progress to a melting stromal ulcer. Cyclosporine does not activate collagenase, hence it is much safer for chronic use than corticosteroids, particularly in exophthalmic breeds susceptible to ocular injury.
Cyclosporine does not penetrate well into the inner eye and it is therefore seldom used to treat anterior uveitis. It reaches high concentrations in the cornea, conjunctiva, sclera, and lids, where it is useful for suppressing chronic immune-mediated disease. In treating chronic superficial keratitis (pannus), nictitans plasmacytic conjunctivitis and pigmentary keratitis, topical cyclosporine is effective whether used with topical corticosteroids or in place of corticosteroids. Anecdotal evidence suggests it also is useful to treat nodular scleritis, diffuse scleritis, follicular conjunctivitis and atopic blepharoconjunctivitis.
Recommended frequency is usually twice daily and can be adjusted more or less frequently to effect. For KCS, ophthalmic cyclosporine usually needs to be continued lifelong. For transient ocular surface disorders it may be used periodically as needed.
Dr. Renee Kaswan is a Diplomate in the College of Veterinary Ophthalmologists and former professor of ophthalmology at the University of Georgia College of Veterinary Medicine, where she taught for 17 years.
She devotes her career to investigating the causes of KCS in man and dog, and developing cyclosporine ophthalmic as the first truly therapeutic agent to treat this common disease.
Renee is internationally distinguished as the 'Queen of Dog tears' and aspires to similar recognition in human ophthalmology with the eventual approval of Restasis.
Though cyclosporine is often used in veterinary ophthalmology, one of its primary indications in veterinary health is for use as an immunosuppressant for immune-mediated diseases. A recent article in
Veterinary Practice News highlights the efficacy of the oral capsules when treating atopic dogs, comparing it favorably to other commonly used treatment-options. To read the published article, click here.
The information contained on this site is general in nature and is intended for use as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the products shown, nor is the information intended as medical advice or diagnosis for individual health problems or for making an evaluation as to the risks and benefits of using a particular product. You should consult your doctor about diagnosis and treatment of any health problems. Information and statements have not been evaluated by the Food and Drug Administration ("FDA"), nor has the FDA approved the products to diagnose, cure or prevent disease.
Wedgewood Pharmacy compounded veterinary preparations are not intended for use in food and food-producing animals.
Some states restrict the information we may provide about controlled substances. Please select your state below.
405 HERON DRIVE SUITE 200 • SWEDESBORO, NJ 08085-1749 | © 2004-2017 WEDGEWOOD PHARMACY, ALL RIGHTS RESERVED.
The information contained on this site is general in nature and is intended for use as an informational aid. It does not cover all possible uses, actions, precautions, side effects, or interactions of the medications shown, nor is the information intended as medical advice or diagnosis for individual health problems or for making an evaluation as to the risks and benefits of using a particular medication. You should consult your doctor about diagnosis and treatment of any health problems. Information and statements have not been evaluated by the Food and Drug Administration ("FDA"), nor has the FDA approved the medications to diagnose, cure or prevent disease.
Medications compounded by Wedgewood Pharmacy are prepared at the direction of a veterinarian. Wedgewood Pharmacy compounded veterinary preparations are not intended for use in food and food-producing animals.